November 15, 2005
Vancouver, Canada – iCo Therapeutics Inc. announced today that Andrew Rae, iCo’s Chief Executive Officer, will present at the BioFinance Early Phase 2005 Conference to be held November 16, 2005 in Toronto, Ontario. Thirty-six emerging life science companies from across North America will present to investors, venture capitalists and pharmaceutical executive, among others.
Mr. Rae’s presentation will take place on November 16, 2005 at 2:20pm EST in room CR-2a at the MaRS Collaboration Centre in Toronto. For more information about the conference, visit the conference website at http://www.biofinance.ca/earlyphase/home.htm.
iCo seeks out and develops or modifies approved or near-approved therapies to treat a variety of conditions within isolated biological environments. Because the drugs have already been through extensive preclinical and clinical testing, and in some cases regulatory approval, development risk and time to commercialization is significantly decreased.
About iCo Therapeutics, Inc.
iCo Therapeutics Inc. is an emerging, Vancouver-based biotechnology company focused on developing pre-existing drugs for a range of new conditions affecting isolated biological environments – areas such as the eye, spinal cord, or joints – where locally-administered application of these therapies would have minimal systemic distribution and fewer safety issues.
For more information, visit the company website at: https://icotherapeutics.com.
Business Development Contact:
Dr. John Clement, CTO
Mr. John Meekison, CFO